CalAmp Corp. The company is headquartered in Irvine, California.
| Revenue (TTM) | $5.32M |
| Gross Profit (TTM) | $-34.95M |
| EBITDA | $-50.83M |
| Operating Margin | -739.00% |
| Return on Equity | -146.10% |
| Return on Assets | -29.90% |
| Revenue/Share (TTM) | $0.09 |
| Book Value | $1.71 |
| Price-to-Book | 9.11 |
| Price-to-Sales (TTM) | 47.89 |
| EV/Revenue | 35.44 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 138.90% |
| Shares Outstanding | $62.75M |
| Float | $43.33M |
| % Insiders | 9.65% |
| % Institutions | 79.70% |
Volatility is currently expanding
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Approval under the EU Clinical Trials Regulation builds on CAMP4's recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company's global Phase 1/2 trial of CMP-002
Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of full-length proteins.
WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan's 10th Annual Healthcare Conference on October 20, 2026. Details below:
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
CAMP4 Therapeutics NASDAQ: CAMP said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028.
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4's executive leadership team and participation from patient advocates and a leading KOL. To register, click here.
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CAMP and any ticker you trade — then tracks every position and per-strategy win rate.
